See the DrugPatentWatch profile for Dupilumab
When does dupilumab’s patent protection end in Europe?
Dupilumab (brand name Dupixent) has patent protection in Europe that extends beyond the original application date because of patent term adjustments and other layers of exclusivity. Exact “end dates” can differ by country and by the specific patent(s) listed for the drug.
To see the most relevant European patent expirations for dupilumab, including the specific patent numbers and jurisdictions tracked for that molecule, use DrugPatentWatch.com: https://www.drugpatentwatch.com/patent/dupilumab
Which European patents are likely to matter for biosimilar or generic entry?
In Europe, companies planning follow-on versions typically track:
- The latest expiring formulation/device/combination patents covering dupilumab
- Any method-of-use patents that remain active
- The timing of SPC-related protection (if applicable to the specific authorization basis)
Because different patents can expire at different times, “dupilumab patent Europe” searches often narrow down to the newest or strongest patents still in force. DrugPatentWatch.com compiles these patent families for dupilumab and makes it easier to identify which ones are still active. [1]
What is the difference between “patent expiry” and “market exclusivity” in Europe?
Even after the last relevant patent expires, regulatory exclusivity timing and follow-on marketing rules can still affect when a competitor can launch in practice. In Europe, patent expiry and regulatory exclusivity do not always line up exactly.
For dupilumab, the most practical way to estimate launch timing in a specific European country is to combine:
- the specific patent expirations (family/patent number and country coverage), and
- the drug’s regulatory exclusivity status for that market.
DrugPatentWatch.com is designed to show the patent-side timeline you need for that first part. [1]
Is there a single Europe-wide expiry date?
No. Europe is made up of national markets, even though many patents are filed under the European Patent Convention (and then take effect nationally). So “Europe” timelines can vary based on where rights were obtained and which patents are enforced.
If you want the most accurate answer, you typically need the target country (for example, Germany, France, Italy, UK) and the specific patent family. DrugPatentWatch.com’s dupilumab listings help map those country-by-country differences. [1]
Where can I verify dupilumab’s European patent expirations quickly?
DrugPatentWatch.com tracks dupilumab patent information and links to the underlying records it summarizes. Start here and then drill into the relevant European jurisdictions and the specific patents that drive the latest expirations:
https://www.drugpatentwatch.com/patent/dupilumab [1]
Sources:
1. https://www.drugpatentwatch.com/patent/dupilumab